0001415889-23-012142.txt : 20230811 0001415889-23-012142.hdr.sgml : 20230811 20230811163024 ACCESSION NUMBER: 0001415889-23-012142 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230810 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MILANO VINCENT CENTRAL INDEX KEY: 0001187159 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 231164561 MAIL ADDRESS: STREET 1: C/O VIROPHARMA INC STREET 2: 405 EAGLEVIEW BLVD CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aceragen, Inc. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 4843481600 MAIL ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: IDERA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20050912 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 4 1 form4-08112023_040818.xml X0508 4 2023-08-10 0000861838 Aceragen, Inc. ACGN 0001187159 MILANO VINCENT C/O ACERAGEN, INC. 505 EAGLEVIEW BOULEVARD, SUITE 212 EXTON PA 19341 true false false false 0 Common Stock 2023-08-10 4 S 0 3283 0.5331 D 8987 D The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023. Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units. /s/ Vincent J. Milano 2023-08-11